bluebird bio Inc (NASDAQ:BLUE) announced two new appointments as part of the company’s ongoing preparation for commercial readiness. Susanna High was named chief operating officer and Andrew Obenshain was named senior vice president and head of Europe.
“I’m thrilled to welcome Susanna and Andrew to bluebird bio,” said Nick Leschly, chief bluebird. “As bluebird becomes more operationally complex and prepares for commercialization in Europeand the U.S., they will be key to rounding out our growing leadership reach and depth to meet the challenge. Both Susanna and Andrew have not only very relevant experiences, but importantly they believe strongly in our mission and the value of a purpose-driven culture.”
Ms. High brings more than 20 years of strategic and operational experience in growing biopharmaceutical companies. Prior to joining bluebird, she worked at Alnylam Pharmaceuticals, Inc., holding increasing responsibilities for company strategy, business planning, portfolio and program management, alliance management, information technology and broader organizational capability building initiatives. Prior to her time at Alnylam, Ms. High worked at Millennium Pharmaceuticals (now Takeda Oncology). Ms. High received her BA in Economics and Business Management, Financial Planning and Analysis from Università ‘Luigi Bocconi’ and her MBA from the Massachusetts Institute of Technology – Sloan School of Management.
Mr. Obenshain was most recently at Shire in Paris, France where he was the General Manager of France and Benelux overseeing a portfolio including seven rare disease products. Prior to Shire, he spent eight years at Genzyme and Sanofi holding roles of increasing responsibility in business development, marketing and global commercial operations. Mr. Obenshain received his MBA from Northwestern University’s Kellogg School of Management, and his BA in Genetics, Cell and Developmental Biology from Dartmouth College. (Original Source)
Shares of Bluebird bio closed yesterday at $68.65, up $8.30 or 13.75%. BLUE has a 1-year high of $83.94 and a 1-year low of $35.37. The stock’s 50-day moving average is $56.99 and its 200-day moving average is $52.88.
On the ratings front, BLUE stock has been the subject of a number of recent research reports. In a report released yesterday, Cantor analyst Elemer Piros reiterated a Sell rating on BLUE, with a price target of $37, which reflects a potential downside of 46% from last closing price. Additionally, Wedbush’s David Nierengarten maintained a Buy rating on the stock and has a price target of $95.
According to TipRanks.com, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Elemer Piros and David Nierengarten have a yearly average return of 1.0% and 27.7% respectively. Piros has a success rate of 38% and is ranked #1901 out of 4239 analysts, while Nierengarten has a success rate of 52% and is ranked #53.
Overall, one research analyst has rated the stock with a Sell rating, 2 research analysts have assigned a Hold rating and 12 research analysts have given a Buy rating to the stock. When considering if perhaps the stock is under or overvalued, the average price target is $95.25 which is 39% above where the stock closed yesterday.
bluebird bio, Inc. is a clinical-stage biotechnology company. Its integrated product platform includes gene therapy, cancer immunotherapy, and gene editing.